Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib or CC-486 + CHO(E)P in CD30 Negative Peripheral T-Cell Lymphomas
NCT04803201Phase 2Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2021
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib, azacitidine in peripheral T-cell lymphoma (PTCL), sponsored by Cancer and Leukemia Group B. Started Oct 2021; status: recruiting.
02
Drugs
duvelisibazacitidine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04803201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803201.